Press Trust of IndiaNov 25, 2021 16:04:23 IST
New Delhi: Diversified entity ITC on Thursday confirmed that it’s creating a nasal spray for COVID-19 prevention for which it has initiated clinical trials.
Developed by scientists at ITC Life Sciences and Technology Centre (LSTC), Bengaluru, the corporate plans to market the nasal spray beneath the Savlon model as soon as it will get all of the requisite regulatory approvals, in line with sources.
When contacted for feedback, a spokesperson of ITC stated, “We are unable to share more details at the current moment as the clinical trials are underway.” The spokesperson declined to touch upon an in depth question on the place is the clinical trial being accomplished, from the place the business manufacturing could be accomplished when authorised and beneath what model the nasal spray could be marketed.
However, sources stated the corporate had obtained approvals from ethics committees and is registered with Clinical Trial Registry-India (CTRI) for clinical trials of the nasal spray which is designed to arrest the virus on the entry level within the nasal cavity itself.
They additional stated the product has the potential to be efficient and secure in stopping an infection and transmission of COVID-19 together with the prevailing measures of hygiene really useful by well being authorities.
ITC’s LSTC has been on the core of the corporate’s drive for science-led product innovation to help and construct its big selection of product portfolio.
The firm’s R&D groups have been instrumental in creating a variety of progressive well being and hygiene choices that have been commercially made obtainable beneath the Savlon model, throughout the pandemic.